Rosalo Paeste, MD
Internal Medicine · Waipahu, HINPI 1548349590
Payments from drug & device makers
Across 821 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Amgen$2K
- Boehringer Ingelheim$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- GSK$1K
- plus $8K from 27 others
What the payments were for
- Speaking & faculty fees$9104%
- Travel & lodging$370%
- Food & beverage$21,32595%
- Education$690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 150 | $5,366 |
| Amgen(2 entities) | 62 | $2,484 |
| Boehringer Ingelheim | 63 | $2,325 |
| Novo Nordisk | 76 | $1,753 |
| Lilly USA, LLC | 58 | $1,303 |
| GSK | 80 | $1,107 |
| Amarin Pharma, Inc. | 32 | $1,007 |
| AbbVie(2 entities) | 53 | $1,000 |
| Johnson & Johnson | 40 | $833 |
| Bayer | 29 | $763 |
| Gilead | 19 | $545 |
| Novartis | 20 | $501 |
| Sanofi-aventis U.S. LLC | 16 | $361 |
| Pfizer | 7 | $355 |
| Esperion Therapeutics, Inc. | 12 | $351 |
| Arbor Pharmaceuticals, Inc. | 31 | $347 |
| Ironwood Pharmaceuticals, Inc | 18 | $325 |
| Insmed, Inc. | 6 | $320 |
| Merck | 14 | $271 |
| Biohaven Pharmaceuticals, Inc. | 6 | $167 |
| E.r. Squibb & Sons, L.L.C. | 7 | $158 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $87 |
| Nestle Healthcare Nutrition Inc. | 4 | $84 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Kowa Pharmaceuticals America, Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Avanir Pharmaceuticals, Inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,341 in reported general payments places this provider in the 95th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 92 | $103,563 |
| JardianceEmpagliflozin | 73 | $86,180 |
| LinzessLinaclotide | 47 | $60,326 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $57,126 |
| OzempicSemaglutide | 26 | $49,473 |
| Xigduo XrDapaglifloz Propaned/Metformin | 41 | $41,248 |
| EliquisApixaban | 34 | $40,849 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $40,133 |
| JanuviaSitagliptin Phosphate | 29 | $36,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $29,347 |
| VascepaIcosapent Ethyl | 26 | $25,669 |
| XareltoRivaroxaban | 13 | $13,274 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,777 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,936 |
| Raloxifene Hcl | 90 | $7,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $2,325 | $143,306124 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $5,366 | $122,627133 claims |
| MerckJanumet Xr, Januvia, Janumet | $271 | $86,13571 claims |
| AbbVieLinzess | $1,000 | $60,32647 claims |
| Novo NordiskOzempic | $1,753 | $49,47326 claims |
| PfizerEliquis | $355 | $40,84934 claims |
| GSKTrelegy Ellipta | $1,107 | $29,34745 claims |
| Johnson & JohnsonXarelto | $833 | $13,27413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Waipahu
- Charlie SonidoWaipahu$34K
- Nenita Bala-AlbanoWaipahu$11K
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.